Table 1 Baseline characteristics in patients with diabetes
2004–2006 n = 1066 | 2007–2009 n = 1507 | 2010–2012 n = 1523 | 2013–2016 n = 1835 | |||||
|---|---|---|---|---|---|---|---|---|
Median age, years (IQR) | 67 (59–73) | 67 (60–74) | 68 (61–75) | 69 (61–75) | ||||
Male sex | 780 | 73.2 | 1061 | 70.4 | 1058 | 69.5 | 1301 | 70.9 |
Family history of ischemic heart disease | 486 | 45.6 | 671 | 44.5 | 697 | 45.8 | 795 | 43.3 |
Active smoker | 239 | 22.4 | 313 | 20.8 | 335 | 22.0 | 363 | 19.8 |
Comorbidity | ||||||||
Hypertension | 834 | 78.2 | 1272 | 84.4 | 1353 | 88.8 | 1583 | 86.3 |
Previous ischemic stroke | 37 | 3.5 | 52 | 3.5 | 60 | 3.9 | 75 | 4.1 |
Atrial fibrillation | 86 | 8.1 | 141 | 9.4 | 159 | 10.4 | 219 | 11.9 |
Peripheral artery disease | 101 | 9.5 | 162 | 10.7 | 167 | 11.0 | 184 | 10.0 |
Heart failure | 116 | 10.9 | 186 | 12.3 | 155 | 10.2 | 163 | 8.9 |
Renal disease | 32 | 3.0 | 51 | 3.4 | 67 | 4.4 | 92 | 5.0 |
Mean eGFR, mL/min (IQR) | 84 (65–101) | 88 (68–107) | 91 (71–108) | 90 (71–108) | ||||
Median BMI, kg/m2 (IQR) | 29 (26–32) | 29 (26–33) | 29 (26–33) | 29 (26–33) | ||||
Modified Charlson Comorbidity Index score | ||||||||
0 points | 853 | 80.0 | 1111 | 73.7 | 1111 | 72.9 | 1286 | 70.1 |
1 point | 152 | 14.3 | 275 | 18.2 | 252 | 16.5 | 298 | 16.2 |
2 point | 58 | 5.4 | 105 | 7.0 | 144 | 9.5 | 207 | 11.3 |
≥ 3 points | 3 | 0.3 | 16 | 1.1 | 16 | 1.1 | 44 | 2.4 |
CAD extent | ||||||||
1 VD | 307 | 28.8 | 450 | 29.9 | 502 | 33,0 | 570 | 31.1 |
2 VD | 269 | 25.2 | 336 | 22.3 | 312 | 20.5 | 400 | 21.8 |
3 VD | 438 | 41.1 | 456 | 30.3 | 348 | 22.8 | 393 | 21.4 |
Diffuse VD | 52 | 4.9 | 265 | 17.6 | 361 | 23.7 | 472 | 25.7 |
Medication | ||||||||
Statin | ||||||||
Before | 868 | 81.4 | 1244 | 82.5 | 1223 | 80.3 | 1441 | 78.5 |
After | 972 | 92.7 | 1349 | 91.4 | 1358 | 90.4 | 1598 | 88.6 |
Aspirin | ||||||||
Before | 876 | 82.2 | 1200 | 79.6 | 1162 | 76.3 | 1279 | 69.7 |
After | 941 | 89.7 | 1284 | 87.0 | 1285 | 85.5 | 1446 | 80.2 |
ADP-inhibitor | ||||||||
Before | 32 | 3.0 | 42 | 2.8 | 63 | 4.1 | 135 | 7.4 |
After | 519 | 49.5 | 655 | 44.4 | 651 | 43.3 | 763 | 42.3 |
Vitamin K antagonists | ||||||||
Before | 91 | 8.5 | 126 | 8.4 | 131 | 8.6 | 144 | 7.8 |
After | 123 | 11.7 | 159 | 10.8 | 151 | 10.0 | 181 | 10.0 |
Non-vitamin K antagonists | ||||||||
Before | 0 | 0.0 | 0 | 0.0 | 7 | 0.5 | 88 | 4.8 |
After | 0 | 0.0 | 0 | 0.0 | 14 | 0.9 | 107 | 5.9 |
Beta-blocker | ||||||||
Before | 732 | 68.7 | 894 | 59.3 | 820 | 53.8 | 867 | 47.2 |
After | 820 | 78.2 | 1050 | 71.1 | 1005 | 66.9 | 1084 | 60.1 |
ACE inhibitor | ||||||||
Before | 500 | 46.9 | 758 | 50.3 | 736 | 48.3 | 755 | 41.1 |
After | 540 | 51.5 | 791 | 53.6 | 733 | 48.8 | 727 | 40.3 |
ARB | ||||||||
Before | 290 | 27.2 | 494 | 32.8 | 505 | 33.2 | 609 | 33.2 |
After | 302 | 28.8 | 490 | 33.2 | 499 | 33.2 | 613 | 34.0 |
Thiazides | ||||||||
Before | 231 | 21.7 | 317 | 21.0 | 331 | 21.7 | 298 | 16.2 |
After | 247 | 23.5 | 309 | 20.9 | 317 | 21.1 | 281 | 15.6 |
Calcium channel blocker | ||||||||
Before | 423 | 39.7 | 621 | 41.2 | 662 | 43.5 | 705 | 38.4 |
After | 446 | 42.5 | 695 | 47.1 | 733 | 48.8 | 811 | 45.0 |
Insulin | ||||||||
Before | 349 | 32.7 | 495 | 32.8 | 503 | 33.0 | 547 | 29.8 |
After | 377 | 35.9 | 538 | 36.4 | 524 | 34.9 | 572 | 31.7 |
Non-insulin | ||||||||
Before | 644 | 60.4 | 936 | 62.1 | 1042 | 68.4 | 1346 | 73.4 |
After | 630 | 60.1 | 934 | 63.3 | 1035 | 68.9 | 1306 | 72.4 |